MYCN and neuroblastoma: Knockout of MYCN protein by targeting with siRNA, or alternatively, destabilizing the protein using an inhibitor of the upstream PI3K signaling pathway, has been shown as an effective preclinical therapy for neuroblastoma (81, 82).